At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13 enrolled
Drug / intervention
Taiwan ACE Beadsdevice
Likely dose
Lipiodol with doxorubicin followed by Taiwan ACE BeadsAI-extracted
Key inclusion· 5
- ✓Age 18 or older, both genders
- ✓Confirmed diagnosis of hepatocellular carcinoma by biopsy OR imaging criteria in high-risk patients
- ✓BCLC intermediate stage with tumor diameter 3-6 cm and Child-Pugh class <9
- ✓Candidate for transarterial chemoembolization and evaluable by imaging (ultrasound, MRI, or CT)
Key exclusion· 11
- ✕Portal vein invasion, extrahepatic metastases, or other malignancies
- ✕Evidence of hepatic decompensation: total bilirubin >2, PT >3 seconds, AST >500, ALT >500, Child-Pugh ≥9, refractory ascites, active bleeding, encephalopathy, or severe infection
- ✕Tumor diameter <3 cm or >6 cm
- ✕Renal dysfunction: creatinine >2.0 mg/dL or eGFR <50%
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Radiopaque Microsphere (Hydrophilic Series) for Hepatoma Embolization Therapy
In Brief
A clinical study evaluating Taiwan ACE Beads for Cancer of Liver. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of Radiopaque Microsphere (T-ACE Beads) interventional therapy for patients with liver cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of Liver
CountriesTaiwan
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedJul 2016
Primary CompletionDec 2016
Study CompletionJan 2017
TodayJul 2026
First PostedJul 7, 2016
Enrollment StartApr 1, 2016
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.0 years ago
Interventions
Taiwan ACE Beadsdevice
Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.